AKT1 and Ewing sarcoma: Targeting the IGF1R/PI3K/AKT pathway has been shown to sensitize Ewing Sarcoma to BET bromodomain inhibitors, inducing a strong synergistic response and potent apoptosis in combination both in vitro and in vivo59.